Maravai Lifesciences SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 4, 2026, 4:02 p.m. ETView on SEC.gov
Financial statements and exhibits
AI summary, unreviewedMaravai LifeSciences Q3 2026 revenue rises 10.1% to $45.9 million and full-year revenue and adjusted EBITDA guidance is raised
8-KAug. 6, 2026, 4:05 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits